



## GENMAB WINS SCRIP'S BIOTECH COMPANY OF THE YEAR AWARD

*Summary: Genmab has won the 2007 Scrip Biotech Company of the Year award.*

**Copenhagen, Denmark; December 5, 2007** – Genmab A/S (OMX: GEN) announced today it has won the 2007 Scrip Biotech Company of the Year award. The award was presented December 4, 2007 at an awards ceremony and gala dinner at the London Hilton on Park Lane hotel.

The award recognizes Genmab's accomplishments during 2006 and 2007 including our work to bring new products closer to their first markets, raise capital, enter significant licensing agreements, maintain strong management, address unmet medical needs through development of our new technology UniBody<sup>®</sup> and to transform Genmab from an early stage to a more mature world leading biotechnology company.

“Receiving the Scrip Award is a testament to the skill and efficiency of all Genmab employees who have worked hard to make our business grow. We are delighted to have won and are honored to receive this year's Scrip Award for Biotech Company of the Year,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer at Genmab.

### **About Genmab A/S**

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit [www.genmab.com](http://www.genmab.com).

*This press release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.*

# GENMAB WINS SCRIP'S BIOTECH COMPANY OF THE YEAR AWARD

Genmab<sup>®</sup>; the Y-shaped Genmab logo<sup>®</sup>; HuMax<sup>®</sup>; HuMax-CD4<sup>®</sup>; HuMax-CD20<sup>®</sup>; HuMax-EGFr<sup>™</sup>; HuMax-IL8<sup>™</sup>; HuMax-TAC<sup>™</sup>; HuMax-HepC<sup>™</sup>; HuMax-CD38<sup>™</sup>; and UniBody<sup>®</sup> are all trademarks of Genmab A/S.

Contact: Helle Husted, Sr. Director, Investor Relations  
T: +45 33 44 77 30; M: +45 25 27 47 13; E: [hth@genmab.com](mailto:hth@genmab.com)

###